{"entity":{"id":"nct04986423","kind":"trial","name":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer","aka":[],"tldr":"A phase 2 trial of ZEN-3694, Enzalutamide in prostate cancer, run by Zenith Epigenetics, now recruiting.","summary":"ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT04986423 by Zenith Epigenetics, with 200 participants planned, started 2021-09-08 and due to reach its primary completion in 2026-12. Interventions recorded: ZEN003694, Enzalutamide. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04986423","url":"https://clinicaltrials.gov/study/NCT04986423"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["androgen-deprivation","epigenetic-drugs"],"targets":[],"drugs":["zen-3694","enzalutamide"],"companies":["zenith-epigenetics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04986423","phase":"2","setting":"A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer","sponsor":"Zenith Epigenetics","started":"2021-09-08","startedType":"actual","enrolled":200,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04986423/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"},{"id":"epigenetic-drugs","kind":"technology","name":"Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)","route":"/technologies/epigenetic-drugs/"}],"drug":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"zen-3694","kind":"drug","name":"ZEN-3694","route":"/drugs/zen-3694/"}],"company":[{"id":"zenith-epigenetics","kind":"company","name":"Zenith Epigenetics","route":"/companies/zenith-epigenetics/"}]}}